Top

Published in:

01-03-2012 | Original Article

Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer

Authors: Chang Moo Kang, Yong Eun Chung, Jeong Youp Park, Jin Sil Sung, Ho Kyoung Hwang, Hye Jin Choi, Hyunki Kim, Si Young Song, Woo Jung Lee

Published in: Journal of Gastrointestinal Surgery | Issue 3/2012

Abstract

Background

Margin-negative pancreatectomy provides only chance to cure pancreatic cancer. However, borderline resectable pancreatic cancer (BRPCa) has the risk of incomplete palliative resection.

Materials and Methods

We retrospectively reviewed 32 patients with BRPCa who underwent a pancreatectomy following preoperative chemoradiation therapy (CCRT (+)/Px group) and compared these patients with those with resectable pancreatic cancer (RPCa) who underwent pancreatectomy without preoperative CCRT (CCRT (−)/Px group, n = 104).

Results

Eighteen patients (56.2%) showed more than 50% significant pathological response to CCRT. The degree of pathological responses showed a positive relationship between final pT stage (p = 0.075). More frequent vascular resection (p < 0.001), transfusion (p = 0.076), and longer operation time were observed in the CCRT(+)/Px group. However, similar R0 resection rates (p = 0.272), lower pT stage (p < 0.001), smaller number of metastastic lymph nodes (p = 0.002), and lower incidence of lymph node metastasis (p = 0.032) were noted in the CCRT(+)/Px group. The overall disease-specific survival were similar (median survival, 30.5 months (95% CI; 23.6–37.4) vs. 26.3 months (95% CI; 15.9–36.7), p = 0.709), and no statistical differences in cancer recurrence risks were noted between the two groups (p = 0.505).

Conclusion

Pancreatectomy following preoperative neoadjuvant CCRT can be a potential strategy for margin-negative resection in BRPCa patients.

Office. KNS. Annual report on the cause of death statistics-2007. . Available form: URL: http://www.nso.go.kr (Korean)

Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4(6):567–579.PubMedCrossRef

Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005;9(7):922–927.PubMedCrossRef

Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008; 207(4):510–519.PubMedCrossRef

Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 2007;110(6):1227–1234.PubMedCrossRef

Lowy AM. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg 2008;12(9):1600–1608.PubMedCrossRef

Kao PS, Chang SC, Wang LW, et al. The impact of preoperative chemoradiotherapy on advanced low rectal cancer. J Surg Oncol 2010;102(7):771–777.PubMedCrossRef

Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16(7):1727–1733.PubMedCrossRef

National Comprehensive Cancer Network (NCCN). NCCN updates pancreatic adenocarcinoma guidelines. Available at; http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf, accessed February 01 2011.

10.

Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19–9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;73(4):1148–1154.PubMedCrossRef

11.

Hong SP, Park JY, Jeon TJ, et al. Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2008;98(5):881–887.PubMedCrossRef

12.

Howard TJ, Krug JE, Yu J, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006;10 (10):1338–1345; discussion 1345–1336.PubMedCrossRef

13.

Nagakawa T, Sanada H, Inagaki M, et al. Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg 2004;11(6):402–408.PubMedCrossRef

14.

Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246(1):52–60.PubMedCrossRef

15.

Winter JM, Cameron JL, Campbell KA, et al. 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10(9):1199–1210; discussion 1210–1191.PubMedCrossRef

16.

Chun YS, Milestone BN, Watson JC, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010;17(11):2832–2838.PubMedCrossRef

17.

Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control 2008;15(4):295–307.PubMed

18.

Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206(5):833–846; discussion 846–838.PubMedCrossRef

19.

Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127(11):1335–1339.PubMedCrossRef

20.

Murakami Y, Uemura K, Sudo T, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010;211(2):196–204.PubMedCrossRef

21.

Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13(7):1337–1344.PubMedCrossRef

22.

Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15(1):165–174.PubMedCrossRef

23.

Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011;18(3):619–627.PubMedCrossRef

24.

Aristu J, Canon R, Pardo F, et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003;26(1):30–36.PubMedCrossRef

25.

Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89(2):314–327.

26.

Pipas JM, Barth RJ, Jr., Zaki B, et al. Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005;12(12):995–1004.PubMedCrossRef

27.

Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13(9):1201–1208.PubMedCrossRef

28.

Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035–1046.PubMedCrossRef

29.

Katz MH, Pisters PW, Lee JE, Fleming JB. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 2011;18(3):608–610.PubMedCrossRef

Title: Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer
Authors: Chang Moo Kang
Yong Eun Chung
Jeong Youp Park
Jin Sil Sung
Ho Kyoung Hwang
Hye Jin Choi
Hyunki Kim
Si Young Song
Woo Jung Lee
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 3/2012
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-011-1784-3

At a glance: The STEP trials

Springer Medicine

Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer

Abstract

Background

Materials and Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2012

Impact of Biomarkers Expression Before and After Portal Vein Embolization on Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases

Dysphagia and Gastroesophageal Junction Resistance to Flow Following Partial and Total Fundoplication

Evaluation of Upper and Lower Gastrointestinal Histology in Patients with Ileal Pouches

Clinical Significance of Indefinite for Dysplasia on Pouch Biopsy in Patients with Underlying Inflammatory Bowel Disease

Tumor Size and Depth Predict Rate of Lymph Node Metastasis in Colon Carcinoids and Can Be Used to Select Patients for Endoscopic Resection

Intrahepatic Cholangiocarcinoma: Clinicopathological Differences Between Peripheral Type and Hilar Type